{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T04:19:01Z","timestamp":1728101941471},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,4]]},"DOI":"10.7759\/cureus.70848","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T16:41:55Z","timestamp":1728060115000},"source":"Crossref","is-referenced-by-count":0,"title":["Post-COVID-19 Multisystem Inflammatory Syndrome in Adults (MIS-A) With Elevated Levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) Treated With Anakinra: A Case Report"],"prefix":"10.7759","author":[{"given":"Maria","family":"Christaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentini","family":"Samanidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelos","family":"Liontos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Revekka","family":"Konstantopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haralampos","family":"Milionis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta P","year":"2020","unstructured":"Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020, 395:1033-4.","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/10408363.2016.1269310","article-title":"The intriguing role of soluble urokinase receptor in inflammatory diseases","volume":"54","author":"Desmedt S","year":"2017","unstructured":"Desmedt S, Desmedt V, Delanghe JR, Speeckaert R, Speeckaert MM. The intriguing role of soluble urokinase receptor in inflammatory diseases. Crit Rev Clin Lab Sci. 2017, 54:117-33. 10.1080\/10408363.2016.1269310","journal-title":"Crit Rev Clin Lab Sci"},{"key":"ref3","unstructured":"IDSA guidelines on the diagnosis of COVID-19. serologic testing. (2024). https:\/\/www.idsociety.org\/practice-guideline\/covid-19-guideline-serology\/."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI140970","article-title":"Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2","volume":"130","author":"Diorio C","year":"2020","unstructured":"Diorio C, Henrickson SE, Vella LA, et al.. Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2. J Clin Invest. 2020, 130:5967-75. 10.1172\/JCI140970","journal-title":"J Clin Invest"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1172\/JCI145301","article-title":"Inflammatory syndromes associated with SARS-CoV-2 infection: dysregulation of the immune response across the age spectrum","volume":"130","author":"Weatherhead JE","year":"2020","unstructured":"Weatherhead JE, Clark E, Vogel TP, Atmar RL, Kulkarni PA. Inflammatory syndromes associated with SARS-CoV-2 infection: dysregulation of the immune response across the age spectrum. J Clin Invest. 2020, 130:6194-7. 10.1172\/JCI145301","journal-title":"J Clin Invest"},{"key":"ref6","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)31094-1","article-title":"Hyperinflammatory shock in children during COVID-19 pandemic","volume":"395","author":"Riphagen S","year":"2020","unstructured":"Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020, 395:1607-8.","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021680","article-title":"Multisystem inflammatory syndrome in U.S. children and adolescents","volume":"383","author":"Feldstein LR","year":"2020","unstructured":"Feldstein LR, Rose EB, Horwitz SM, et al.. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020, 383:334-46. 10.1056\/NEJMoa2021680","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.10369","article-title":"Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2","volume":"324","author":"Whittaker E","year":"2020","unstructured":"Whittaker E, Bamford A, Kenny J, et al.. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA. 2020, 324:259-69. 10.1001\/jama.2020.10369","journal-title":"JAMA"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.01.054","article-title":"Multisystem inflammatory syndrome in children and adults (MIS-C\/A): case definition & guidelines for data collection, analysis, and presentation of immunization safety data","volume":"39","author":"Vogel TP","year":"2021","unstructured":"Vogel TP, Top KA, Karatzios C, et al.. Multisystem inflammatory syndrome in children and adults (MIS-C\/A): case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2021, 39:3037-49. 10.1016\/j.vaccine.2021.01.054","journal-title":"Vaccine"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00211","article-title":"NLRP3 inflammasome-a key player in antiviral responses","volume":"11","author":"Zhao C","year":"2020","unstructured":"Zhao C, Zhao W. NLRP3 inflammasome-a key player in antiviral responses. Front Immunol. 2020, 11:211. 10.3389\/fimmu.2020.00211","journal-title":"Front Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.11.149","article-title":"Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: results of a prospective, open-label, interventional study","volume":"103","author":"Balkhair A","year":"2021","unstructured":"Balkhair A, Al-Zakwani I, Al Busaidi M, et al.. Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: results of a prospective, open-label, interventional study. Int J Infect Dis. 2021, 103:288-96. 10.1016\/j.ijid.2020.11.149","journal-title":"Int J Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0110555","article-title":"Soluble urokinase plasminogen activator receptor as a marker for use of antidepressants","volume":"9","author":"Haastrup E","year":"2014","unstructured":"Haastrup E, Grau K, Eugen-Olsen J, Thorball C, Kessing LV, Ullum H. Soluble urokinase plasminogen activator receptor as a marker for use of antidepressants. PLoS One. 2014, 9:e110555. 10.1371\/journal.pone.0110555","journal-title":"PLoS One"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.780641","article-title":"Soluble urokinase plasminogen activator receptor (suPAR) as a biomarker of systemic chronic inflammation","volume":"12","author":"Rasmussen LJ","year":"2021","unstructured":"Rasmussen LJ, Petersen JE, Eugen-Olsen J. Soluble urokinase plasminogen activator receptor (suPAR) as a biomarker of systemic chronic inflammation. Front Immunol. 2021, 12:780641. 10.3389\/fimmu.2021.780641","journal-title":"Front Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-02897-4","article-title":"Soluble urokinase plasminogen activator receptor\u00a0(suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia","volume":"24","author":"Rovina N","year":"2020","unstructured":"Rovina N, Akinosoglou K, Eugen-Olsen J, Hayek S, Reiser J, Giamarellos-Bourboulis EJ. Soluble urokinase plasminogen activator receptor\u00a0(suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Crit Care. 2020, 24:187. 10.1186\/s13054-020-02897-4","journal-title":"Crit Care"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020060829","article-title":"Soluble urokinase receptor (SuPAR) in COVID-19-related AKI","volume":"31","author":"Azam TU","year":"2020","unstructured":"Azam TU, Shadid HR, Blakely P, et al.. Soluble urokinase receptor (SuPAR) in COVID-19-related AKI. J Am Soc Nephrol. 2020, 31:2725-35. 10.1681\/ASN.2020060829","journal-title":"J Am Soc Nephrol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1159\/000524560","article-title":"IL-1 mediates tissue-specific inflammation and severe respiratory failure in COVID-19","volume":"14","author":"Renieris G","year":"2022","unstructured":"Renieris G, Karakike E, Gkavogianni T, et al.. IL-1 mediates tissue-specific inflammation and severe respiratory failure in COVID-19. J Innate Immun. 2022, 14:643-56. 10.1159\/000524560","journal-title":"J Innate Immun"},{"key":"ref17","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-4642(20)30215-7","article-title":"Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study","volume":"4","author":"Davies P","year":"2020","unstructured":"Davies P, Evans C, Kanthimathinathan HK, et al.. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. Lancet Child Adolesc Health. 2020, 4:669-77.","journal-title":"Lancet Child Adolesc Health"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/PCC.0000000000000078","article-title":"Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis\/sepsis\/multiple organ dysfunction\/macrophage activating syndrome in critically ill children*","volume":"15","author":"Rajasekaran S","year":"2014","unstructured":"Rajasekaran S, Kruse K, Kovey K, et al.. Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis\/sepsis\/multiple organ dysfunction\/macrophage activating syndrome in critically ill children*. Pediatr Crit Care Med. 2014, 15:401-8. 10.1097\/PCC.0000000000000078","journal-title":"Pediatr Crit Care Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.32078","article-title":"Rapid resolution of post-COVID-19 inflammatory syndrome in an adult with targeted inhibition of interleukin-1B","volume":"14","author":"Felix M","year":"2022","unstructured":"Felix M, Farrukh L, Modi S, Peredo-Wende R. Rapid resolution of post-COVID-19 inflammatory syndrome in an adult with targeted inhibition of interleukin-1B. Cureus. 2022, 14:e32078. 10.7759\/cureus.32078","journal-title":"Cureus"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/IPC.0000000000001028","article-title":"Multisystem inflammatory syndrome in an adult with COVID-19-a trial of anakinra: a case report","volume":"29","author":"Aggarwal A","year":"2021","unstructured":"Aggarwal A, Cohen E, Figueira M, et al.. Multisystem inflammatory syndrome in an adult with COVID-19-a trial of anakinra: a case report. Infect Dis Clin Pract (Baltim Md). 2021, 29:e420-3. 10.1097\/IPC.0000000000001028","journal-title":"Infect Dis Clin Pract (Baltim Md)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/295410-post-covid-19-multisystem-inflammatory-syndrome-in-adults-mis-a-with-elevated-levels-of-soluble-urokinase-plasminogen-activator-receptor-supar-treated-with-anakinra-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T16:41:58Z","timestamp":1728060118000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/295410-post-covid-19-multisystem-inflammatory-syndrome-in-adults-mis-a-with-elevated-levels-of-soluble-urokinase-plasminogen-activator-receptor-supar-treated-with-anakinra-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,4]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.70848","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,4]]}}}